Dechu Puliyanda is a Nephrology physician affiliated with Cedars-Sinai Medical Center. OpenAlex indexes 77 publications with 1,591 citations (h-index 21).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8700 Beverly Blvd
West Hollywood, CA 900481865
Telephone
310-423-4747Provider last certified this registry record 21 Jan 2022.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20251 payment
- Apellis Pharmaceuticals, Inc.Program year20253 payments
- Novartis Pharmaceuticals CorporationProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
54.2%Nitrofuran Antibacterial54.2%Nitrofurantoin100%Part D<11 patientsMetabolism & gastrointestinal
45.8%H2 blocker45.8%Famotidine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2005–2008 per NIH RePORTER. The latest:
- CLINICAL TRIAL: FOCAL SEGMENTAL GLOMERULOSCLEROSIS TRIAL
Lundquist Institute for Biomedical Innovation at Harbor-Ucla Medical Center
FY2008$1,463M01RR000425 - FOCAL SEGMENTAL GLOMERULOSCLEROSIS TRIAL
Lundquist Institute for Biomedical Innovation at Harbor-Ucla Medical Center
FY2007$2,159M01RR000425 - THE ROLE OF POLYOMA VIRUS IN RENAL TRANSPLANTATION
la Biomed Res Inst/ Harbor Ucla Med Ctr
FY2005$47,285M01RR000425
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A rare case of hyperuricemia and acute kidney injury in a kidney transplant patient
Pediatric Nephrology
2025 - Daratumumab for Treatment of Recurrent FSGS and PGNMID in Kidney Transplant
American Journal of Transplantation
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Beth Karlan, MD
Cedars-Sinai Medical Center
Raj Makkar, MD
Cedars-Sinai Medical Center
Paul Noble, MD
Cedars-Sinai Medical Center
Stephen Freedland, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”